Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.360
-0.030 (-2.16%)
At close: Jul 11, 2025, 4:00 PM
1.380
+0.020 (1.47%)
After-hours: Jul 11, 2025, 7:59 PM EDT
Inovio Pharmaceuticals Revenue
Inovio Pharmaceuticals had revenue of $65.34K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $283.10K, down -60.52% year-over-year. In the year 2024, Inovio Pharmaceuticals had annual revenue of $217.76K, down -73.83%.
Revenue (ttm)
$283.10K
Revenue Growth
-60.52%
P/S Ratio
148.89
Revenue / Employee
$2,113
Employees
134
Market Cap
69.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.76K | -614.25K | -73.83% |
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.30M | 80.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INO News
- 5 days ago - INOVIO to Present at Upcoming Scientific Conference - PRNewsWire
- 9 days ago - INOVIO Announces Pricing of $25 Million Public Offering - PRNewsWire
- 10 days ago - INOVIO Announces Proposed Public Offering - PRNewsWire
- 11 days ago - Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development - GlobeNewsWire
- 2 months ago - Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 2 months ago - Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript) - Seeking Alpha
- 2 months ago - INOVIO to Present at Upcoming Scientific and Investor Conferences - PRNewsWire